

中華民國婦癌醫學會 開會通知單

受文者：全體會員

發文日期：112 年 04 月 24 日

發文字號：婦癌字第 1120424 號

速別：速件

密等及解密條件或保密期限：普通

附件：常年會費繳費通知單及會員資料更新、講師介紹、大會平面圖

開會事由：第二十七屆台灣癌症聯合學術年會暨第十四屆第三次會員大會

開會時間：112 年 05 月 06 日（星期六）上午 09:30~13:00

開會地點：臺大醫院國際會議中心 101 會議室&臺大醫學院體育館一樓
（臺北市徐州路二號）


主持人：呂建興 理事長

聯絡人及電話：陳曉慧 聯絡電話：(02) 2873-5423

說明：

- 一、第二十七屆台灣癌症聯合學術年會擬於 5 月 6 日~7 日（星期六~日）假臺大國際會議中心舉行實體會議，會中邀請許多國內外專家學者蒞臨演講與大家分享癌症新知，懇請撥冗參加。
- 二、本會擬於 5 月 6 日（六）12:10~13:00, 假臺大醫院國際會議中心 101 會議室舉辦第十四屆第三次會員大會，屆時請撥冗準時出席。
- 三、報到流程：本次大會採用刷卡方式報到，過卡即可完成報到手續。（過卡時電腦只會讀取身分證或是健保卡的數字條碼，不會有其他資料外洩的問題發生。）

會員



四、本會邀請演講嘉賓時段：



中華民國婦癌醫學會 議程
Society of Gynecologic Oncology, Republic of China

日期 | 5月6日(星期六)
地點 | 臺大醫院國際會議中心 101

Time	Topic	Speaker	Moderator
09:30-09:35	Opening Remarks	呂建興 理事長 Chien-Hsing Lu 中華民國婦癌醫學會	
09:35-10:25	Long and Winding Road to the IP Carboplatin Therapy for Ovarian Cancer	藤原 惠一 教授 Pro. Keiichi Fujiwara (Japan)	莊其穆 教授 Chi-Mu Chuang 臺北榮總
10:25-11:10	Treatment Algorithm for Frontline Ovarian Cancer: From What Perspectives Should We Consider?	Dr. Domenica Lorusso (Rome Italy)	劉文雄 主任 Wen-Shiung Liou 高雄榮總
11:10-11:20	Coffee Break		
11:20-12:05	Optimizing Therapeutic Strategies for Early-Stage Ovarian Clear Cell Carcinoma (OCCC)	黃韻如 教授 Ruby Yun-Ju HUANG, M.D. Ph.D. 臺大醫院	許博欽 教授 Bor-Ching Sheu 臺大醫院
12:05-12:10	Closing	呂建興 理事長 Chien-Hsing Lu 中華民國婦癌醫學會	
12:10-13:00	第 14 屆第 3 次會員大會		

五、檢附檔案：

- 會員繳費通知/會員資料更新表格：為方便會務順利運作，並有效將學術相關活動訊息即時傳達給會員，懇請撥冗填寫。
(如附件一)
- 講師簡介(如附二)
- 大會平面圖(如附件三)

理事長 呂建興

【附件一、會費繳費通知/會員資料更新】

親愛的會員，您好！

本學會承蒙您的支持，對於婦科癌病學術推展，均全力以赴而略有小成。往後，會務的推動仍有賴全體會員鼎力支持期於有成。

為方便會務順利運作，煩請會員繳交112年度常年會費（2000元）。本會劃撥帳號為：14918167，戶名：中華民國婦癌醫學會。

另外，為了解本會會員之變動資料及方便聯絡，若您有任何資料變動，煩請您撥冗詳填下列基本資料，請您填寫後mail至hui0816@hotmail.com(檢附名片亦可)。

恭祝 醫安

會員資料

姓名：

身分證號碼：

現任工作、職位：	
戶籍地址	
通訊地址	
電話(公)(含分機)	
聯絡人	
手機	
Line ID	(懇請填寫方便加入學會群組)
E-Mail	
備註(有任何建議事項或其他更動資料請填此格)	

註：在年度中會員若有任何資料變動，懇請 mail:hui0816@hotmail.com(檢附名片亦可)，謝謝您！

【附件二、TJCC 國內外講師】



藤原 惠一
Keilichi Fujiwara

Current Position :

1. President, International Gynecologic Cancer Society
2. Visiting Professor, Saitama Medical University International Medical Center
3. Professor, International University of Health and Welfare
4. President, NRG Oncology-Japan

Educational Experiences :

1. 1979 Graduate Okayama University School of Medicine, MD
2. 1987 Obtained PhD, Okayama University School of Medicine

Professional Experiences :

1. 2021-Current Position
2. 2017-2019 Chair, Gynecologic Cancer Intergroup
3. 2007-2021 Professor, Gynecologic Oncology, Saitama Medical University Int. Med. Ctr.
4. 1993-2006 Associate Professor, OBGYN, Kawasaki Medical School
5. 1990-1993 Assistant Professor, OBGYN, Kawasaki Medical School
6. 1988-1990 Research Fellow, Gyne Onc. and Exp. Rad. Oncol. Wake Forest University
7. 1979-1986 OBGYN, Okayama University School of Medicine

Awards and Honours :

1. 2022 SGO Presidential Abstract Award
2. 2018 AGO Austria, Weltheim Award

中博盛 101
5/6 (Sat.) 09:35-10:25

Long and Winding Road to the IP Carboplatin Therapy for Ovarian Cancer

Intraperitoneal (IP) chemotherapy has been considered to be an optimal administration route of cytotoxic anticancer drugs for advanced ovarian cancer (AOC), but not accepted as standard chemotherapy because of multiple reasons. When GOG252 trial failed to demonstrate survival benefit of IP carboplatin over intravenous (IV) administration, many physicians believed that IP chemotherapy was dead. However, in the recently published trial (IPoCC Trial), we demonstrated that PFS was significantly prolonged in IP carboplatin arm compared with IV route, and we believe that IP therapy was resuscitated. The reason of the different outcome of these trials seems to be the use of bevacizumab in GOG252 trial, which was not used in IPoCC trial. It is also important to note that IP chemotherapy was effective in all AOC cancer regardless of residual tumor size. Therefore, it is important that IP carbo should be applied for all patient populations without combining bevacizumab.

In recent years, it is also important to incorporate PARP inhibitor (PARPi) after chemotherapy. Selection of PARPi is usually based on the status of BRCA or HRD.

In this talk I will discuss what is the best PARPi when we give IP chemotherapy for AOC.

第27屆台灣癌症聯合學術年會
The 27th Taiwan Joint Cancer Conference

Advancing Integrated Cancer Care through Innovation



Domenica Lorusso

Current Position :

1. Associate Professor of Obstetrics and Gynecology, Catholic University of Sacred Heart of Rome
2. Head of UOCD Clinical Research Program, Fondazione Policlinico Gemelli IRCCS, Rome

Educational Experiences :

1. Attending Physician, Department of Oncology, San Giovanni Hospital, Bellinzona, Switzerland
2. PhD, Obstetrics and Gynecological Sciences, University of Parma (Università degli Studi di Parma)
3. Diploma of Theoretical-Practical Course of Colposcopy, University of Rome
4. Diploma of Theoretical-Practical Course of Hysteroscopy, University of Rome
5. Fellowship: Institute of Gynecological and Obstetric Clinic, Catholic University of Sacred Heart of Rome

Professional Experiences :

1. Head of Phase I Clinical Studies Department, IRCCS National Cancer Institute Foundation, Milan
2. Head of UOCS "Gynecological Medical Therapy", IRCCS National Cancer Institute Foundation, Milan
3. Chair of the Clinical Trials Committee
4. Chair of the International Relationship Committee

Awards and Honours :

1. Head of the International Relations Commission of Multicenter Italian Trials Ovarian Cancer (MITO)
2. Active Member of European Network in Gynecologic Oncologic Trials (ENGOT)
3. Member of Board of Directors of the Gynecologic Cancer InterGroup (GCIg)
4. Member of ESGO Council
5. Scientific Coordinator of ESMO Gynaecological Cancer Congress

中博盛 101
5/6 (Sat.) 10:25-11:10

Treatment Algorithm for Frontline Ovarian Cancer: From What Perspectives Should We Consider?

- Brief overview of available options and algorithm for frontline maintenance landscape in advanced ovarian cancer
- Focus on consideration factors in choosing maintenance treatment, including different genomic profile, and when to add on bevacizumab
- Highlight Niraparib's PRIMA and PRIME results, emphasizing clinical benefits in BRCAmut and/or HRD/BRCawt
- Clinical experience with niraparib in frontline maintenance setting, preferably in BRCAmut and/or HRD/BRCawt patients

第27屆台灣癌症聯合學術年會
The 27th Taiwan Joint Cancer Conference

Advancing Integrated Cancer Care through Innovation



黃韻如
Ruby Yun-Ju HUANG

Current Position :

1. Professor, School of Medicine, College of Medicine, NTU
2. Professor, Graduate Institute of Oncology, College of Medicine, NTU
3. Professor, Graduate Institute of Medical Engineering, College of Engineering, NTU
4. Director, Research Center for Social Innovation, D-School, NTU

Educational Experiences :

1. Doctor of Medicine (M.D.), School of Medicine, College of Medicine, NTU
2. Doctor of Philosophy (Ph.D.), Graduate Institute of Anatomy and Cell Biology, College of Medicine, NTU

Professional Experiences :

1. Professor, School of Medicine, College of Medicine NTU
2. Visiting Professor, Department of Obstetrics & Gynaecology, NUS
3. Visiting Professor, IRCMS, Kumamoto University
4. Principal Investigator, Cancer Science Institute of Singapore, NUS
5. Senior Resident Physician, Department of Obstetrics & Gynaecology, NUH

Awards and Honours :

1. 2018 Yushan Young Fellow Ministry of Education, ROC (Taiwan)
2. 2012 NUHS Clinician Scientist Program Award National University Health System
3. 2012 2012 Aflac-AACR Scholar in Training Award

中博盛 101
5/6 (Sat.) 11:20-12:05

Optimizing Therapeutic Strategies for Early-Stage Ovarian Clear Cell Carcinoma (OCCC)

Ovarian clear cell carcinoma (OCCC) is a histological subtype of epithelial ovarian cancer (OC) with distinct pathological features, molecular profiles, and biological functions. OCCC has high incidence rates in East Asia compared to the West. Therefore, it is a disease with strong Asian impacts. With its relative resistance to conventional treatment regimens and the worst stage-adjusted prognosis amongst OC subtypes, there is an urgent need to optimize therapeutic options and to improve patient outcomes. To achieve this goal, better patient stratification strategies are required. These strategies could derive from comprehensive and in-depth multi-dimensional analysis of tumor heterogeneity. Understanding the inter-tumor heterogeneity could assist us in stratifying OCCC patients based on features that are prognostic or predictive. Dissecting the intra-tumor heterogeneity could, on the other hand, help us understand the intrinsic clonal complexities which could explain therapeutic failure. By addressing the heterogeneity of OCCC via integrating comprehensive research platforms, several molecular and biological subgroups have been identified within OCCC. Particularly, immune-hot features have been identified in early-stage OCCC which are associated with disease recurrence and worse survival outcomes. These immune-hot features could be utilized for the optimization of therapeutic strategies for early-stage OCCC.

